Royalty Pharma plc Depreciation
Royalty Pharma plc (RPRX) reported Depreciation of $2.46 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-05
- Royalty Pharma plc depreciation for the quarter ending 2026-06-30 was $1.29M, a 6.16% decline year-over-year.
- Royalty Pharma plc depreciation for the quarter ending 2026-03-31 was $1.17M.
- Royalty Pharma plc depreciation for the quarter ending 2025-12-31 was $1.20M.
- Royalty Pharma plc depreciation for the quarter ending 2025-09-30 was $1.28M.
- Royalty Pharma plc depreciation for fiscal 2025 was $3.85M.
- Royalty Pharma plc depreciation for fiscal 2024 was $0.00.
- Royalty Pharma plc depreciation for fiscal 2023 was $0.00.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $2.46M 10-Q · filed 2026-08-05 | $3.66M derived: sum of 3 quarters · filed 2026-08-05 | $4.94M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $1.17M 10-Q · filed 2026-05-06 | $2.37M derived: sum of 2 quarters · filed 2026-05-06 | $3.64M derived: sum of 3 quarters · filed 2026-05-06 | $5.02M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $2.47M derived: sum of 2 quarters · filed 2026-02-11 | $3.85M derived: sum of 3 quarters · filed 2026-08-05 | $3.85M 10-K · filed 2026-02-11 |
| 2025-09-30 | $1.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.66M derived: sum of 2 quarters · filed 2026-08-05 | $2.66M 10-Q · filed 2025-11-05 | $2.66M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.38M 10-Q · filed 2026-08-05 | $1.38M derived: sum of 3 quarters · filed 2026-08-05 | $1.38M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-05-06 | $0.00 derived: sum of 3 quarters · filed 2026-05-06 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $0.00 derived: sum of 2 quarters · filed 2026-02-11 | $0.00 10-K · filed 2026-02-11 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-06 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |